Lilly Business: By the Numbers
$24.5B
Lilly’s 2020 revenue, up 10% over 2019
45M
patients helped by Lilly medicines in 2019
>50%
revenue from products launched since 2014
New Data on Existing Medicines
Lilly Cautionary Statement Regarding Forward-Looking Statements
This document contains forward-looking statements that are based on management’s current expectations, but actual results may differ materially due to various factors. The company’s operations, results, business, goals and strategy may be affected by factors including, but not limited to, the risks and uncertainties in pharmaceutical research and development; competitive developments; regulatory actions; the extent and duration of the COVID-19 pandemic; litigation and investigations; business development transactions; economic conditions; and changes or developments in laws and regulations, including health care reform.
For additional information about the factors that affect the company’s business, please see the company’s latest Forms 10-K, 10-Q, and any 8-Ks filed with the Securities and Exchange Commission. The company undertakes no duty to update forward-looking statements except as required by applicable law.
Find more detail on Lilly’s environmental, social and governance priorities, strategies and operations.